EMEA-003334-PIP01-22 - paediatric investigation plan

camlipixant

Key facts

• Active substance:
  camlipixant
• Therapeutic area:
  Pneumology-allergology
• Decision number:
  P/0067/2023
• PIP number:
  EMEA-003334-PIP01-22
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of unexplained or chronic refractory cough
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Compliance check done:
  Ne

Decision

P/0067/2023 : EMA decision of 10 March 2023 on the granting of a product specific waiver for camlipixant (EMEA-003334-PIP01-22)

Reference Number: EMA/84285/2023